What is Vicebio?
Vicebio is at the forefront of redefining respiratory disease prevention with its proprietary Molecular Clamp technology. This innovative platform enables the development of next-generation vaccines designed for broad protection and ease of manufacturing. The company is dedicated to tackling significant global health challenges, evidenced by its robust pipeline of multipathogen respiratory vaccines. Vicebio's solutions are targeted towards healthcare providers and organizations seeking advanced strategies for respiratory disease management.
How much funding has Vicebio raised?
Vicebio has raised a total of $100M across 1 funding round:
Series B
$100M
Series B (2024): $100M with participation from UniQuest, venBio Partners, Goldman Sachs, and TCG Crossover
Key Investors in Vicebio
UniQuest
UniQuest provides expertise in communication messaging and lead scoring modeling, utilizing multi-channel communications to enhance prospect-to-applicant rates and yield. They offer strategic communication channels including phone, web chat, live chat, e-mail, instant messaging, and Skype.
venBio Partners
venBio Partners is a life sciences investment firm focused on novel therapeutics for unmet medical needs, managing significant capital and emphasizing positioning portfolio companies for acquisition. They provide strategic guidance on development plans to enhance patient care.
Goldman Sachs
Goldman Sachs is a global investment banking, securities, and investment management firm offering a wide range of financial services, including M&A advisory, underwriting, asset management, and strategic advisory services.
What's next for Vicebio?
The recent major enterprise-level funding, including a significant strategic investment, positions Vicebio for accelerated growth and pipeline advancement. This capital infusion is expected to fuel further research and development, potentially expanding clinical trials and preparing for broader market entry. The company's focus on multipathogen respiratory vaccines suggests a strategic move towards addressing a wide spectrum of respiratory threats, aiming to establish a dominant position in the preventative health sector.
See full Vicebio company page
